All In Biotech

Drug Trial Radar · NCT01880424

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Last checked: Nov 19, 2026Latest source record: Sep 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,722 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,722

Actual

Start

Jul 2013

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Ironwood Pharmaceuticals, Inc.
First posted
Jun 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand. The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).

Conditions

  • Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions

  • PlaceboDrug

    matching Placebo Capsules, Oral, once daily

  • LinaclotideDrug

    Linaclotide 290 ug Capsules, Oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-week Abdominal Pain/Abdominal Discomfort Weekly ResponderTime frame: Baseline and Weeks 1-12 during the Treatment Period
  2. 12-week Irritable Bowel Syndrome (IBS) Degree of Relief ResponderTime frame: Baseline and Weeks 1-12 during the Treatment Period

Locations

82 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    North Little Rock, Arkansas

  • Research Site

    Phoenix, Arkansas

  • Research Site

    Artesia, California

  • Research Site

    Chula Vista, California

  • Research Site

    Encino, California

  • Research Site

    North Hollywood, California

  • Research Site

    Orange, California

  • Research Site

    Riverside, California

  • Research Site

    San Diego, California

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Brandon, Florida

  • Research Site

    Brooksville, Florida

  • Research Site

    Doral, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Lauderdale Lakes, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Addison, Illinois

  • Research Site

    Evansville, Indiana

  • Research Site

    Crowley, Louisiana

  • Research Site

    Monroe, Louisiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Chesterfield, Michigan

  • Research Site

    Wyoming, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Billings, Montana

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Brooklyn, New York

  • Research Site

    Great Neck, New York

  • Research Site

    New York, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Salisbury, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Franklin, Ohio

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.